The findings come from two large phase 3 clinical trials—MODIFY I and MODIFY II—designed to determine the efficacy of the drug bezlotoxumab alone or in combination with the drug actoxumab for the ...
Pfizer advances second-generation C. diff vaccine with Phase 2 data expected in 2025. Analyst maintains cautious optimism as investor sentiment remains muted on vaccine efforts. Pfizer hosted a ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results